Neuromuscular

Commenting on recent advances and persistent challenges for these patients, the associate professor of clinical occupational therapy at USC Keck Hospital spoke on the need to increase equity and access to care. [WATCH TIME: 6 minutes]

The agent had previously demonstrated positive results in a phase 2a setting, with favorable trends on modified Unified MSA Rating Scale scores across a 12-week period.

The associate professor of clinical occupational therapy at USC Keck Hospital discussed the role of occupational therapists and other medical professionals in the care of these patient populations. [WATCH TIME: 3 minutes]

The first-of-its-kind, peer-nominated recognition program will celebrate the comprehensive care community in multiple sclerosis.

The associate professor of clinical occupational therapy at USC Keck Hospital discussed the growing awareness for the care of these patients, as well as the integration of occupational therapists. [WATCH TIME: 2 minutes]

With AMX0035 expected to be submitted to the FDA for review in the coming months, the investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital chimed in to share her thoughts on its potential. [WATCH TIME: 3 minutes]

Jess Holguin, OTD, OT/L, spoke on the unique role occupational therapists can play for patients with neuromuscular and movement disorders.

Data from the STRIDE patient registry showed that treatment was also associated with a delay in pulmonary function decline for those with Duchenne muscular dystrophy.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 24, 2021.

The expanded access program is designed to provide individuals with ALS who are not eligible to enroll in the Healey ALS Platform Trial access to CNM-Au8.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed future neuroimaging projects the center is evaluating and where the focus turns to next. [WATCH TIME: 3 minutes]

Both the 200-mg and 350-mg dose groups showed numerically advantageous differences over placebo in secondary end points such as average daily pain score and 30% reduction in ADP.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending September 18, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 17, 2021.

Participants in the pilot study saw improvements in short-term memory, attention, and executive functioning.

The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.

Initiated by Biogen, the study will evaluate the effectiveness of the treatment in patients previously treated with risdiplam (Evrysdi; PTC Therapeutics).

The combination drug of sodium phenylbutyrate–taurursodiol has been shown to functional decline in patients with amyotrophic lateral sclerosis compared with placebo in the phase 2/3 CENTAUR trial.

The division chief of vascular neurology at the University of Utah discussed the misperceptions surrounding the field of neurology, as well as the importance of increasing fellowship training.

The division chief of vascular neurology at the University of Utah discussed the driving force behind the national shortage of neurologists and its effect on patient care.

Here's what is coming soon to NeurologyLive.

Jennifer Majersik, MD, MS, commented on how the AAN, as well as current neurologists and specialists, can help generate interest in the field of neurology to meet patient needs.

Additional functional outcomes and gait analysis showed mixed results when using botulinumtoxinA in those with CP.

Jennifer Majersik, MD, MS, division chief of vascular neurology at the University of Utah, discussed contributing factors to the neurologist shortage, as well as ongoing efforts to increase interest in the field.